Crispr Therapeutics AG vs Fiverr International Ltd — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Fiverr International Ltd trades at $8.72 (market cap $310.61M). The key difference: Crispr Therapeutics AG is far larger — about 15.7× Fiverr International Ltd's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Fiverr International Ltd for 62 Days on average.
| CRSP | FVRR | |
|---|---|---|
Market Cap | $4.88B | $310.61M |
Volume | 2,861,747 | 381,459 |
Sector | Health | Media |
52-Week High | $74.92 | $23.60 |
52-Week Low | $44.34 | $8.47 |
Typical Hold Time | 77 Days | 62 Days |
Enterprise Value | $3.30B | $63.00M |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Fiverr International (FVRR) trades at $8.64, up 1.65% on the day, amid a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. Revenue for 2025 reached $430.91M with a net income margin of 7.18%, though 2026 revenue is projected to dip to $418M. Valuation ratios appear attractive with a P/E of 10.67 and P/S of 0.76, but the stock faces headwinds from AI disruption compressing demand for freelance services, as highlighted in recent news.
The stock's outlook is cautious, with analyst consensus leaning Hold (76.47%) and a price target of $10.50 offering potential upside. Key risks include AI-driven market shifts and competitive pressures, while the current low valuation may appeal to value investors if the company navigates transitional challenges successfully.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →